Mylan And Biocon Launch Semglee Insulin Glargine In US

Seeking Biosimilar Status And Interchangeability Designation For Lantus Rival

 
• By David Wallace
  
Insulin glarine
Mylan and Biocon have introduced their Semglee insulin glargine in the US • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin